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The nature of crosspriming immunogens for CD8+
T cell responses is highly controversial. By using
a panel of T cell receptor-like antibodies specific for
viral peptides bound tomouseDbmajor histocompat-
ibility complex class I molecules, we show that an
exceptional peptide (PA224-233) expressed as a viral
minigene product formed a sizeable cytosolic pool
continuouslypresented forhoursafterprotein synthe-
sis was inhibited. PA224-233 pool formation required
active cytosolic heat-shock protein 90 but not ER
g96 and uniquely enabled crosspriming by this pep-
tide. These findings demonstrate that exceptional
class I binding oligopeptides that escape proteolytic
degradation are potent crosspriming agents. Thus,
the feeble immunogenicity of natural proteasome
products in crosspriming can be attributed to their
evanescence indonorcells andnot anabsolute inabil-
ity of cytosolic oligopeptides to be transferred to and
presented by professional antigen-presenting cells.
INTRODUCTION
Direct antigen presentation is based on proteasome-initiated
degradation of defective ribosomal products (DRiPs) and other
rapidly degraded endogenous translation products (Eisenlohr
et al., 2007; Yewdell, 2007). Typically, peptides of eight or
more residues are transported by the transporter associated
with antigen processing (TAP) into the endoplasmic reticulum
(ER) where final trimming of COOH-terminal residues is mediated
by ER-associated aminopeptidase (ERAAP). Peptide binding
releases nascent class I molecules from the loading complex,
initiating their transport to the plasma membrane for recognition
by CD8+ T cells.In viral infections, direct presentation enables CD8+ T cell ac-
tivation by virus-infected cells, including dendritic cells (DCs),
which can initiate naive CD8+ T cell response in lymph nodes
and spleen. But what if viruses cannot (or will not) express their
proteins in DCs? In this case, an alterative pathway exists,
termed crosspriming, where DCs process antigens acquired
from infected cells and present them to naive CD8+ T cells
(Shen and Rock, 2006). Controversy swirls around virtually every
aspect of crosspriming.
A substantial literature has grown around the concept
that crosspriming is mediated by DC acquisition of glucose-
regulated protein 94 (GRP94) (also known as glycoprotein 96
[gp96]) and other chaperones bearing oligopeptides derived
from proteasomal antigen degradation (Srivastava, 2002). It
has proven difficult, however, for many laboratories to recover
peptides bound to gp96 purified from antigen-presenting cells,
or even to demonstrate that gp96 binds to oligopeptides with
an affinity consistent with its proposed role in crosspriming
(Demine and Walden, 2005; Javid et al., 2007; Nicchitta et al.,
2004; Wallin et al., 2002; Ying and Flatmark, 2006). Purified
gp96 and a variety of other chaperones demonstrate antigen-
specific crosspriming activity, but this activity is weak, and the
adjuvant role of contaminants (e.g., lectins, bacterial lipopoly-
saccharide) in the phenomenon is a concern. Heat-shock protein
90 (HSP90) has been recovered from cells bound to truncated
forms of a model antigen (Kunisawa and Shastri, 2006), but the
crosspriming activity of such complexes has not been demon-
strated in the context of intact cells as immunogens. Moreover,
seven laboratories recently published studies pointing to protea-
some substrates rather than proteasome products as the source
of crosspriming antigens (Basta et al., 2005; Donohue et al.,
2006; Freigang et al., 2007; Gasteiger et al., 2007; Norbury
et al., 2004; Shen and Rock, 2004; Wolkers et al., 2004). This
conclusion jibes with the original observation by Rammensee
and colleagues that antigenic oligopeptides are recovered only
from cells expressing class I molecules capable of presenting
the peptides (Falk et al., 1990). Further, the finding that cytosolicImmunity 28, 787–798, June 2008 ª2008 Elsevier Inc. 787
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Peptide-Based CrossprimingFigure 1. Detection of Db-Peptide Complexes on Cells Infected with rVVs Expressing Cytosolic or ER-Targeted Peptides
(A) L-Db cells were infected with rVVs encoding for Mg peptides (black line), ES peptide (gray line), or uninfected control (solid gray).
(B) T2-D
b cells were infected with rVVs encoding for Mg peptides (black line), ES peptide (gray line), or uninfected control (solid gray). Each graph represents
infections with rVVs encoding the peptide that the indicated antibody is directed to. Binding of Fabs to live cells was determined by flow cytometry. L-Db infections
were repeated more than six times. T2-Db infections were repeated two times.oligopeptides are rapidly destroyed by endopeptidases and
aminopeptidases (half-life on the order of 10 s) (Reits et al.,
2004) is inconsistent with the hypothesis that oligopeptides exist
in stable complexes with molecular chaperones.
A key advance in the antigen presentation field was the intro-
duction of antibodies with TCR-like specificities, generated by
standard hybridoma technology or by screening of antibody
phage display libraries (Andersen et al., 1996; Denkberg and
Reiter, 2006; Porgador et al., 1997). Such reagents enable mea-
surement of cell-surface major histocompatibility complex
(MHC) class I peptide complexes with great precision by flow cy-
tometry. Here we describe the generation and characterization
of a panel of TCR-like phage-displayed antibodies specific for
well-defined influenza A virus (IAV) peptides bound to H-2Db
molecules. We then use these phage antibodies to study the
cell biology and immunology of oligopeptides introduced into
the cytosol and ER of antigen-presenting cell and crosspriming
donor cells as biosynthesized minigene products.
RESULTS
Isolation of Human Recombinant Antibodies with
TCR-like Specificity to Influenza Virus-Derived
Peptide-MHC Complexes
To generate a panel of TCR-like antibodies specific for IAV-Db-
restricted determinants, we selected a large nonimmune library
consisting of 3.7 3 1010 unique human recombinant phage Fab
antibody fragments (de Haard et al., 1999) for binding to purified788 Immunity 28, 787–798, June 2008 ª2008 Elsevier Inc.H-2Db complexed with PA224-233, NP366-374, or PB1-F262-70.
These determinants top the defined anti-IAV immunodominance
hierarchy in B6 mice. Out of numerous candidates identified, we
chose the Fabs that demonstrated the best signal-to-noise ratio
and sensitivity. As seen in Figure S1 available online, the three
Fabs chosen selectively recognized both purified Db and cell-
surface Db complexed with their cognate determinants. The
threshold for peptide recognition on peptide-pulsed EL4 cells
with low-temperature-induced peptide-receptive Db molecules
occurred at 109 M. This is similar to the sensitivity of the 25-
D1.16 mAb, which is specific for Kb-SIINFEKL complexes. This
reagent represents ‘‘gold standard’’ for highly sensitive and
specific TCR-like antibody recognition (Porgador et al., 1997).
We next tested the ability of the TCR-like Fabs (FabTCRs) to
bind to endogenous complexes generated from cytosolic or
ER-targeted minigene products expressed by recombinant
vaccinia viruses (rVVs) (see schematic of rVVs in Figure S2). Mini-
gene products are typically expressed at very high copy num-
bers (tens of thousands per cell) relative to peptides generated
from full-length proteins (ten to a few thousand copies per cell)
(Princiotta et al., 2003). Each of the six minigene products tested
was easily detected by its cognate FabTCR (Figure 1). Addition of
a signal sequence increased the numbers of cell-surface com-
plexes very slightly for PB1-F262-70 and 5-fold for NP366-374
and PA224-233.
To determine the TAP dependence of complex formation, we
infected human T2-Db cells with the rVVs (T2 cells are EBV-trans-
formed lymphoblasts that lack both TAP1 and TAP2 genes, and
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Peptide-Based CrossprimingFigure 2. Kinetics of Db-Peptide Presentation on L-Db Cells after rVV Infections
Cell-surface Db-peptide amounts were measured on L-Db cells infected with rVVs expressing ES-224 (A), ES-366 (B), ES-PB1-F2 (C), Mg-224 (D), Mg-366 (E), or
Mg-PB1-F2 (F). Infected cells were treated with protein synthesis inhibitors (PSI) or BFA at times indicated by arrows. In (G), PSI were added to VV-ES-224-in-
fected cells at the times indicated, and cell-surface Db-PA224 amounts were determined. Addition of PSI at 150 min and 180 min reveals PA224-233 pools that result
in increases of 70 and 105 fluorescence units of Db-PA224-233 complexes, respectively. Each experiment was repeated at least three times.consequently, cytosolic peptides have limited access to the ER).
This revealed that, as expected, each of the cytosolic minigene
products demonstrated only slight TAP-independent presenta-
tion, whereas ER targeting bypassed the requirement for TAP
for PB1-F262-70 and PA224-233. Surprisingly, presentation of ER-
targeted NP366-374 remained largely TAP dependent. A possible
explanation is the presence of Ala as the NH2-terminal residue
in NP366-374, because Ala is a preferred residue at the P1 site of
signal peptidase cleavage, which may therefore destroy the pep-
tide when it is translocated via the translocon. If this is the case,
the enhanced ability of ES-NP366-374 to access D
b in L-Db cells
would presumably be due to the ability of the leader sequence
to enhance TAP-mediated antigen presentation. This could be
due to resistance to degradation by cytosolic or ER proteases
or enhanced TAP-mediated transport into the ER of the full-length
ES peptide or, more likely, a NH2-terminally trimmed version.
These findings demonstrate that FabTCRs can be used as
highly specific reagents to precisely quantitate cell-surface Db-
peptide complexes generated from VV-encoded minigenes.
Kinetics of Cell-Surface Complex Presentation
via TCR-like Fabs
We next examined the kinetics of cell-surface complex expres-
sion at 30 min intervals after infection of L-Db cells with rVVs ex-
pressing the three determinants. In each case, cognate peptide-
MHC complexes were first detected by the FabTCRs 60–90 min
after infection and quickly reached Vmax of complex generation
(i.e., the maximal increase in the rate of complex accumulation).
This behavior is similar to expression of Kb-Ova257-264 com-plexes (Princiotta et al., 2003) and is exactly what is expected
for peptides that rapidly achieve saturating amounts of expres-
sion for feeding the class I pathway and require little or no
processing for binding to class I molecules.
Addition of BFA, which blocks MHC egress from the secretory
pathway by inducing Golgi complex disassembly and redistribu-
tion of Golgi complex proteins into the ER (Yewdell and Bennink,
1989), resulted in an immediate block of cell-surface complex
accretion. In the case of ES-PB1-F262-70, BFA caused a steep
and steady decline in surface complexes, indicative of a relatively
low complex stability (t1/2 of 120 min). Under the same condi-
tions, both ER-targeted and cytosolic NP366-374 demonstrated
intermediate complex stability whereas both cytosolic and ER-
targeted PA224-233 generated highly stable complexes. This hier-
archy of complex stability agrees with the stability of complexes
generated with synthetic peptides that we previously reported
(Figure 3 in Chen et al. [2004]), findings that we repeated by using
the FabTCRs (data not shown).
Cellular oligopeptides are believed to be nearly completely
degraded in a few seconds (Reits et al., 2004), so the kinetic
difference between blocking protein synthesis and blocking
surface delivery with BFA should be minimal and difficult to de-
tect when sampling cells at 30 min intervals. This was indeed
the case for NP366-374-D
b and PB1-F262-70-D
b complexes (Fig-
ures 2B, 2C, 2E, and 2F). Db-PA224-233 complexes behaved in
a completely different and highly surprising manner. The delivery
of PA224-233 complexes to the cell surface continued at nearly the
same rate up to 2 hr after addition of protein synthesis inhibitors
(PSI) (Figures 2A and 2D).Immunity 28, 787–798, June 2008 ª2008 Elsevier Inc. 789
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PA224-233 is resistant to the protein synthesis inhibitors we uti-
lized. Based on the mode of action of protein synthesis inhibitors,
we considered this very unlikely (particularly because a number
of potent protein synthesis inhibitors [anisomycin, cyclohexi-
mide, emetine, pactamycin] used individually gave similar re-
sults). We eliminated this possibility by treating cells with protein
synthesis inhibitors at the start of infection and showing that
Db-PA224-233 complex formation was completely inhibited (not
shown). Rather, these findings demonstrate the formation of
a pool of PA224-233 peptide or D
b-PA224-233 complexes that feeds
the class I pathway for hours after protein synthesis shutdown.
The kinetics of pool formation is most consistent with the for-
mer possibility. When we blocked protein synthesis at increasing
times after infection, the size of the pool increased with time of
expression. In the interval between 150 and 180 min, the pool in-
creased from 70 flow units to 105 units (Figure 2G). Notably, this
is twice the amount of complexes delivered to the cell surface
over the identical interval. Because the Vmax of cell-surface com-
plex delivery has been reached by 150 min, the large increase in
the size of the pool over the next 30 min is difficult to reconcile
with a pool of Db-PA224-233 complexes in the secretory pathway
if the size of this pool is directly related to the rate of ER export
and cell-surface complex delivery.
These experiments demonstrate that PB1-F262-70 and
NP366-374 demonstrate kinetic behavior completely consistent
with rapid degradation unless bound to MHC class I molecules,
whereas PA224-233 demonstrates kinetics not previously ob-
served (for either proteins or minigene products) that are consis-
tent with it forming a substantial pool that forms a steady source
of peptides for hours after shutting off its biosynthetic source.
PA224-233 Peptide Cellular Pool Is Dependent
on Cellular HSP90 Activity
The recent report from Kunisawa and Shastri (2006) demonstrat-
ing that HSP90a associates with proteolytic fragments of
KOVAK, a misfolded cytosolic model antigen, prompted us to
examine the effect of cell-permeant small molecule inhibitors of
HSP90. These inhibitors are among the most selective inhibitors
available to probe intracellular pathways. All of the inhibitors used
target the NH2-terminal ATP binding domain of HSP90 family
members. Two of the inhibitors used, 17AAG and 17DMAG, are
second generation geldanamycin analogs with higher potency
than the parent, while the third, radicicol, is chemically distinct
from geldanamycin, and so would be expected to have a distinct
off-target profile. Cells were treated with the given HSP90 inhib-
itor at 30 min after infection to allow viral penetration to occur and
to minimize effects on viral gene expression (Figure 3). Treatment
with each of the inhibitors inhibited Db-PA224-233 cell-surface
complex expression by approximately 20%–30%. This is not
specific for PA224-233, as shown by the fact that NP366-374 and
PB1-F262-70 decreased similarly (data not shown) and probably
reflects a requirement for active HSP90 for maximal VV gene
expression.
To assess the effect of HSP90 inhibitors on PA224-233 pool for-
mation in this experiment, we incubated the cell with protein syn-
thesis inhibitors at 240 min (Figures 3E–3G). This revealed that
each of the HSP90 inhibitors tested eliminated the PA224-233
peptide pool. Importantly, addition of HSP90 inhibitors simulta-790 Immunity 28, 787–798, June 2008 ª2008 Elsevier Inc.neously with PSI failed to diminish complex expression (Fig-
ure 3G), indicating that maintenance of the peptide pool does
not require active HSP90.
The Hsp90 family consists of cytosolic Hsp90a, Hsp90b, the
ER paralog GRP94, and mitochondrial Trap-1, all of which are
sensitive to the panel of HSP90 inhibitors. To identify the relevant
targets involved in PA224-233 peptide pool formation, we trans-
fected L-Db cells with siRNAs specific for HSP90 (a&b) (the
siRNA sequences do not distinguish between these highly simi-
lar genes), GRP94, or Neomycin (negative control). Cells were re-
transfected 4 days after the initial transfection and used 4 days
later. This resulted in a greater than 10-fold specific reduction
in HSP90 and GRP94 as determined by immunoblotting of total
cell lysates (Figure 4A). These cells were infected with the rVV
expressing ER-targeted PA224-233 and tested for PA224-233 pool
formation as described above by the effect of protein synthesis
inhibition on continued complex expression (Figures 4B and
4C). This revealed that mock transfected cells or cells trans-
fected with control siRNA or with GRP94 siRNA exhibited a large
PA224-233 pool that remained completely sensitive to HSP90 inhi-
bition by 17AAG. By contrast, the pool was nearly completely
depleted by HSP90 (a&b) knockdown.
These data demonstrate that the PA224-233 pool is formed in-
dependently of GRP94 but requires functional cytosolic HSP90.
PA224-233 Physically Associates with a HSP90
Inhibitor-Sensitive Receptor in Living Cells
These findings were consistent with the idea that PA224-233 phys-
ically associates with HSP90 or a HSP90-sensitive client. To
investigate the possible interaction of PA224-233 with a cytosolic
receptor, we microinjected L-Db cells with synthetic PA224-233
or PB1-F262-70 (as a control) with a COOH-terminal Lys residue
conjugated with fluorescein at its 3-NH2-group (PA224-233KFl,
PB1-F262-70KFl). Each peptide distributed evenly between cyto-
solic and nuclear compartments (Figures 5A and 5B). This con-
trasts with the findings of Reits et al. (2003) that microinjected
peptides typically concentrate in the nucleus because of their
protection from proteolysis by chromatin. In other experiments
(unpublished observations), we observed that another microin-
jected peptide with Lys-fluorescein (SIINFEKFLL) demonstrates
nuclear localization. It is likely that these differences reflect
chemical differences in the peptides used in these disparate
studies that govern their interaction with cellular constituents.
We measured the mobility of cytosolic PA224-233KFl by fluores-
cence recovery after photobleaching (FRAP) analysis and com-
pared its properties to PB1-F262-70KFl as a control (Figure 5C).
PA224-233KFl demonstrated a substantially slower diffusion coef-
ficient than did PB1-F262-70KFl. Critically, treating cells with
17AAG for 20 min prior to microinjection did not affect the diffu-
sion coefficient of PB1-F262-70KFL but did increase the diffusion
coefficient of PA224-233KFl to match that of PB1-F262-70KFL. It
was of interest to compare the mobility peptides to full-length
proteins. Consistent with Reits et al. (2003), the mobility of
PB1-F262-70KFl was 20% greater than that of GFP, which in
turn was substantially more mobile than a HSP90a-GFPcherry
construct (Figure 5). Importantly, although GFP mobility was
unaffected by 17AAG, HSP90a-GFPcherry demonstrated a sub-
stantial increase in mobility (though less mobile than GFP, as
expected from its larger radius of gyration), providing the initial
Immunity
Peptide-Based CrossprimingFigure 3. Effect of HSP90 Inhibitors on PA224-233 Pool Generation
Cell-surface Db-PA224-233 complexes were determined by flow cytometry at indicated times after infection with VV-ES-224. Cells were treated with PSIs 240 min
after infection (open circles) or left untreated (solid circles) in the presence or absence of HSP90 inhibitors added 30 min or 240 min after infection as indicated.
(A)–(D) are from the same experiment; (E) and (F) are from another experiment. Each experiment was repeated at least three times.
(A) No inhibitor.
(B) Treated with 2 mM Radicicol.
(C) Treated with 2 mM 17DMAG.
(D) Treated with 2 mM 17AAG.
(E) No inhibitor.
(F) 17AAG added 30 min after infection.
(G) 17AAG added 240 min after infection.FRAP evidence for the physical interaction of a HSP90 family
member peptide binding site. This contrasts with HSP90b,
whose mobility is reported to be insensitive to HSP-90 inhibitors
(Picard et al., 2006).
These data demonstrate that 17AAG detectably affects
HSP90 mobility in living cells and are consistent with the conclu-
sion that PA224-233 associates with a cytosolic partner that
requires HSP90 peptide binding activity: either HSP90 itself, or
a client that is rather rapidly altered by HSP90 inhibition.
PA224-233 Peptide Minigene Crossprimes
CD8+ T Cells in B6 Mice
The observation that PA224-233 accumulates in a substantial sta-
ble pool in L-Db cells prompted the question of whether the pool
can be tapped for crosspriming in vivo. To address this question,
we immunized B6 mice via intraperitoneal (i.p.) injection with
rVV-infected L929 cells (i.e., the original nontransfected cells
that do not express Db) that were irradiated with UV light to
destroy residual viral infectivity. We determined the frequency
of local (peritoneal exudate cells [PEC]) and splenic responding
CD8+ T cells by intracellular staining for INF-g after incubation
of antigen-presenting cells (APCs) with peptides corresponding
to the cognate minigene product or to a peptide correspondingto residues B8R20-27, the immunodominant determinant in VV in-
fections in B6 mice. For an estimate of overall anti-VV responses,
we also stimulated responding CD8+ T cells ex vivo with
VV-infected DC2.4 or L-Db cells.
The data in Figure 6A clearly show that L929 cells expressing
NP366-374 and PB1-F262-70 as ER-targeted minigene products fail
to elicit CD8+ T cells responses that are substantially above
background values obtained by stimulating with an irrelevant
peptide. By contrast, cells expressing ER-targeted PA224-233 eli-
cited robust PA224-233-specific responses (Figures 6A and 6B).
Note that cells expressing the nonimmunogenic minigene prod-
ucts elicited vigorous B8R20-27 and total VV-specific CD8
+ T cell
responses, indicating that the nonimmunogenicity of their mini-
gene products cannot be attributed to diminished infectivity or
other factors that limit the crosspriming capacity of these rVVs.
To determine the TAP dependence of crosspriming, we per-
formed a similar experiment in which we replaced L929 cells
with T2 cells (again lacking Db). Both cytosolic and ER-targeted
PA224-233 minigenes crossprimed to a similar extent for PA224-233-
specific responses (Figure 6B). (Note that it is likely that sub-
stantial amounts of ER-targeted peptides persist in the cytosol,
resulting either from inefficient targeting of such small proteins
to the ER or from the recycling of excess peptides from the ERImmunity 28, 787–798, June 2008 ª2008 Elsevier Inc. 791
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Peptide-Based CrossprimingFigure 4. PA224-233 Pool Formation Is Dependent on HSP90 Expression
Cell-surface Db-PA224-233 complexes were determined by flow cytometry at indicated times after infection with VV-ES-224. Cells were transfected twice with
siRNA to knock down HSP90 or GRP94. The second transfection was 4 days after the initial, and cells were used 4 days after the second transfection.
(A) Knockdown of HSP90 and GRP94 in L-Db cells after siRNA transfection was confirmed by immunoblotting.
(B–H) Kinetic flow cytometry of infected cells transfected with siRNA indicated (with Neo siRNA as a control siRNA transfection) or nontransfected. In (F)–(H), cells
were treated with 17AAG at 30 min after infection to demonstrate that pool remained sensitive to HSP90 inhibition. siRNA knockdown followed by kinetics
experiment was repeated two times.to the cytosol [Koopmann et al., 2000; Roelse et al., 1994]). The
TAP independence of cytosolic PA224-233 crosspriming is in
agreement with the finding that cytosolic HSP90 but not
GRP94 is involved in peptide pool formation (Figure 4). We
more directly tested the involvement of functional HSP90 in
PA224-233 crosspriming by treating donor cells with 17AAG dur-
ing rVV infection prior to their introduction into B6 mice (Fig-
ure 6C). This reduced PEC and splenic anti-PA224-233 responses
by 85% while reducing B8R20-27 or overall VV-specific re-
sponse by 15% to 50%.
Next, we examined the requirement for GRP94 in crosspriming
by using human HEK293 cells stably transfected with GRP94-
targeting siRNA (control HEK293 cells were stably transfected
with the same sequence but scrambled). Via immunoblotting,
GRP94 is undetectable in knockdown cells whereas HSP90
amounts are similar between control and knockdown cells (Fig-
ure 6D). Despite the absence of GRP94, both rVVs expressing792 Immunity 28, 787–798, June 2008 ª2008 Elsevier Inc.cytosolic and ER-targeted PA224-233 were effective at crossprim-
ing for PA224-233-specific, B8R20-27-specific, and total VV-
specific CD8+ T cell responses (Figures 6E and 6F).
Crosspriming Is Based on the Presence
of a Large Db-Independent Pool
To characterize the crosspriming pool of PA224-233 in L929 cells,
we measured antigenic peptides recovered from HPLC-fraction-
ated low-molecular-weight acid-soluble material from homoge-
nized cells infected with VV-encoded cytosolic PA224-233 or (as
a negative control) NP366-374. Activity was measured with CD8
+
T cell populations expanded in vitro to each peptide. T cell pop-
ulations demonstrated highly similar picomolar sensitivity to syn-
thetic peptide (data not shown). Large amounts of NP366-374 were
recovered from infected L-Db cells, with recovery of peak anti-
genic activity in fractions that coelute with synthetic NP366-374
(Figure 7A). Antigenic activity in peak fractions could be detected
Immunity
Peptide-Based Crossprimingat a dilution of 1/12,500, whereas activity in infected L929 cells
titrated at least 1000-fold lower amounts. This is consistent
with the classically reported rapid degradation of peptides lack-
ing a high-affinity class I receptor.
PA224-233 was recovered from infected L-D
b cells in even
greater amounts than NP366-374 (Figure 7A). Peak activity coe-
luted with synthetic PA224-233, but considerable amounts of
activity spilled into slower eluting fractions. As with NP366-374,
peak activity titrated to greater than 1/12,500. Most remarkably,
essentially identical amounts of PA224-233 were recovered from
the same fractions of infected L929 cells. This provides a physical
description of a large pool of PA224-233 that exists independently
of Db. Indeed, Db expression has no discernible influence on the
pool size, suggesting that only a small fraction of PA224-233 is
present complexed with Db in infected L-Db cells.
All of our evidence points to the conclusion that the PA224-233
pool is present in the cytosol. We consider it extremely unlikely
that the pool is present as a complex with a class Ia or Ib mole-
cule expressed by L929 cells (particularly because the pool also
exists in T2 cells, which, in addition to lacking TAP, express
Figure 5. PA224-233 Cytosolic Diffusion Is Retarded in a HSP90-
Dependent Manner
Synthetic peptides with an additional COOH-terminal Lys-3-FITC were micro-
injected into L-Db cells.
(A) PA224-233 peptide cellular distribution.
(B) PB1-F262-70 peptide cellular distribution.
(C) Diffusion rates measured by FRAP for microinjected peptides compared to
control GFP and mCherry-HSP90a. 17AAG added to indicated samples 20
min prior to microinjections. FRAP analysis was performed in at least 50 differ-
ent cells for each condition shown. Error bars represent standard error of the
mean. Starred pairs represent significant differences between conditions
(p < .0001).a completely different set of class I molecules becuase they
are of human origin). Based on the unprecedented nature of
the pool, however, we thought it prudent to perform an additional
experiment to characterize the possible contribution of class I
protected peptides to crosspriming in the VV system we employ.
To this end, we immunized mice with L-Db cells infected
with VV-NP366-374, VV-PB1-F262-70, or (as a positive control)
VV-PA224-233. Although cells expressing PA224-233 crossprimed
as above, cells expressing the other minigene products did not
(Figure 7B). Thus, despite the generation of very large numbers
of Db complexed with NP366-374 or PB1-F262-70 peptides, protec-
tion by class I is not sufficient to enable crosspriming, implying
that PA224-233 crosspriming occurs in a class I-independent
manner in the absence or even the presence of Db.
DISCUSSION
Proteasomal protein cleavage generates oligopeptides of
between 3 and 32 residues that are degraded by highly active
cytosolic endopeptidases and aminopeptidases (Kisselev
et al., 1998; Reits et al., 2004). The half-life of oligopeptides in
this aggressively degradative environment is believed to be
10 s. Inasmuch as proteasome-generated peptides are func-
tionless, potentially dangerous agents that can interfere with cel-
lular functions (including impeding the interaction of molecular
chaperones with their substrates), the rapid removal of peptides
and reutilization of amino acids is logical.
Despite this, a considerable literature has accrued regarding
the potential role of GRP94 and other abundant molecular chap-
erones in protecting peptides from degradation and promoting
peptide immunogenicity upon transfer to pAPCs. There is com-
pelling evidence that molecular chaperones have a bona fide role
in activating innate immune receptors (Baker-LePain et al., 2002;
Oizumi et al., 2007). The function of molecular chaperones, how-
ever, in specifically binding and delivering oligopeptides gener-
ated from biosynthesized proteins to pAPCs is controversial.
Molecular chaperones exhibit low affinity for their substrates
(on the order of 0.1 mM), consistent with their need to transiently
interact with clients to promote folding (Flynn et al., 1989, 1991;
Fourie et al., 1994; Ying and Flatmark, 2006). With such a low
affinity, peptides would be protected only fleetingly, achieve
low steady-state amounts in living cells, and dissociate rapidly
upon release from cells and delivery to pAPCs. Although there
is limited evidence for recovery of defined peptides from
GRP94 purified from cells, others have found only minute quan-
tities of peptides bound to GRP94 and have questioned the
peptide-chaperoning function of GRP94 in antigen presentation
(Demine and Walden, 2005; Nicchitta et al., 2004; Wallin et al.,
2002; Ying and Flatmark, 2006). Moreover, molecular chaper-
ones are only weakly immunogenic relative to cell-associated
immunogens, even when loaded in vitro to the maximal extent
attainable with synthetic peptides. Even non-cell-associated
heat-aggregated viruses or proteins are more immunogenic
than the most potent HSP preparations reported (Cho et al.,
2003; Speidel et al., 1997).
On top of this, we and others have provided evidence strongly
supporting a central role for intact proteins in crosspriming
(Basta et al., 2005; Donohue et al., 2006; Freigang et al., 2007;
Gasteiger et al., 2007; Norbury et al., 2004; Shen and Rock,Immunity 28, 787–798, June 2008 ª2008 Elsevier Inc. 793
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Peptide-Based CrossprimingFigure 6. PA224-233 Minigene Product Induces Robust Crosspriming
Mice were immunized intraperitoneally (i.p.) with UV-irradiated L929, T2, or HEK293 cells infected for 6 hr with rVV expressing the minigene products indicated.
Six days later, splenocytes and PECs were tested for IFN-g accumulation after restimulation with indicated peptides or VV-infected DC2.4 or L-Db cells.
(A) Crosspriming with L929 cells infected with ES-224 (black), ES-366 (white), and ES-PB1-F2 (striped).
(B) T2 cells infected with ES-224 (black) or Mg-224 (white).
(C) ES-224 crosspriming with L929 cells treated with 17AAG (white) or untreated (black).
(D) HSP90 and GRP94 amounts in HEK293 cells were measured by western blot with specific antibodies as indicated.
(E) Crosspriming with HEK293 cells with GRP94 stably knocked down infected with ES-224 (black) or Mg-224 (white).
(F) Crosspriming with parental HEK293 cells stably transfected with scramble sequence infected with ES-224 (black) or Mg-224 (white).
Values are subtracted from background obtained from wells receiving no peptides and are expressed as mean ± SE of three individual mice in each group for
splenic responses. For peritoneal responses, PECs were pooled. Each experiment was repeated at least two times.2004; Wolkers et al., 2004). Cellular oligopeptides generated via
signal peptidase liberation or synthesized as cytosolic or ER-tar-
geted minigene products display little to no crosspriming activity
(Gasteiger et al., 2007; Norbury et al., 2004; Serna et al., 2003).
The poor crosspriming capacity of minigene products, consis-
tent with the lack of crosspresentation of minigene products
observed in vitro by Serna et al. (2003), can be explained by their
rapid degradation. Like naturally processed antigenic peptides,
recovery of minigene-encoded minimal peptides from cells is
heavily dependent on the presence of a high-affinity class I re-
ceptor (Anton et al., 1997). More recently, we precisely quanti-
tated cell-surface Kb-Ova257-264 complex expression in cells in-794 Immunity 28, 787–798, June 2008 ª2008 Elsevier Inc.fected with VV-Ova257-264 by using the TCR-like mAb 25-D1.16
(Princiotta et al., 2003). Upon abrogation of protein synthesis,
delivery of Kb-Ova257-264 complexes to the cell surface ceased
rapidly, consistent with the rapid degradation of Ova257-264.
In the present study, we extend these findings to three addi-
tional defined peptides expressed as cytosolic or ER-targeted
minigenes. By using a novel panel of TCR-like Abs to measure
cell-surface Db-peptide complex expression, we found that for
two of the peptides, NP366-374 and PB1-F262-70, the kinetics of
shutdown of complex delivery to the cell surface after inhibiting
protein synthesis was virtually identical to those observed after
BFA blockade of Db-peptide complex egress from the early
Immunity
Peptide-Based Crossprimingsecretory pathway, providing unequivocal evidence for the ab-
sence of a protected peptide pool capable of supplying the class
I pathway. Crucially, these peptides also failed to exhibit sub-
stantial crosspriming activity when expressed in cells lacking Db.
In distinct contrast, whereas BFA rapidly abrogated cell-
surface delivery of PA224-233 complexes, delivery continued for
hours after abrogation of protein synthesis, indicative of a sizable
intracellular pool. This pool is independent of Db expression, as
demonstrated by the crosspriming activity of PA224-233 minigene
products in L929 cells and also the recovery of large amounts of
PA224-233 via acid extraction from the same cells. The TAP inde-
pendence of PA224-233 minigene product crosspriming points to
a cytosolic location for the PA224-233 pool. Consistent with this
interpretation, the PA224-233 pool and its crosspriming activity
is abrogated by selectively interfering with cytosolic HSP90 func-
tion or expression and is unaffected by ER GRP94 knockdown.
Further, we show that upon microinjection, a fluorescent deriva-
tive of PA224-233 diffuses more slowly in the cytosol than an
equivalent form of PB1-F262-70, an effect that is rapidly abro-
gated by addition of a HSP90 inhibitor. This is consistent with
the binding of PA224-233 to a HSP90-dependent cytosolic partner
that retards its diffusion.
We were unable to recover PA224-233 with HSP90-specific an-
tibodies to purify HSP90 from cytosol recovered from semi-in-
tact cells or TX100 lysates (data not shown). Kunisawa and Shas-
tri (2006) recovered numerous fragments of KOVAK from HSP90
antibody pulldowns. It is uncertain, however, whether these pep-
tides directly associate with HSP90, because HSP90 partici-
pates in large complexes containing other client-binding molec-
ular chaperones. Two findings favor the idea that PA224-233 is
only indirectly influenced by HSP90 activity. First, the PA224-233
pool persists for hours after protein synthesis inhibition, suggest-
ing a high-affinity interaction with its chaperone. Second, adding
HSP90 inhibitors at the time of protein synthesis blockade did
not deplete the pre-existing PA224-233 pool. This strongly sug-
Figure 7. Physical Demonstration of the
PA224-233 Peptide Pool in L929 Cells
(A) Acid-soluble peptides recovered from L-Db or
L929 cells infected for 5 hr with VV-PA224-233
(top) or VV-NP366-374 (bottom) were separated by
HPLC and fractions were tested for antigenic ac-
tivity with CD8+ T cell lines raised to each peptide
by ICS for IFN-g.
(B) Crosspriming in spleen (top) and PECs (bot-
tom) by rVV minigene L-Db cells infected with
ES-224 (black), ES-366 (white), and ES-PB1-F2
(striped) as described in Figure 6. Values are
expressed as mean ± SE of three individual mice
in each group for splenic responses.
gests that pool formation is not directly
based on association of PA224-233 with
HSP90, because HSP90 inhibitors would
be predicted to cause either the release
of PA224-233 from HSP90 and rapid prote-
olysis or the Ub-dependent degradation
of HSP90-bound PA224-233 (Isaacs et al.,
2003). In support of the rapid action of
HSP90 inhibitors, we show that 17AAG rapidly increases the
diffusion of HSP90a in living cells.
Notably, inactivation or depletion of HSP90 and GRP94 had
little effect on the crosspriming capacity of B8R20-27-specific
CD8+ T cells or polyclonal anti-VV CD8+ T cell responses. It is
possible that other molecular chaperones are involved in cross-
priming for these natural gene products. We believe it is unlikely,
however, that this involves chaperoned peptides generated from
these proteins.
Our findings demonstrate that oligopeptides are capable of
crosspriming if they are spared from proteolysis. Thus, the inabil-
ity of other minigene products or efficiently liberated peptides
(such as signal sequences or oligopeptides released from Ub-
fusion proteins by Ub-hydrolases) to crossprime can be directly
attributed to their evanescence and not the general inability of
oligopeptides to survive transfer to, and further processing in,
pAPCs. This strongly implies that the poor immunogenicity of
rapidly degraded model proteins, and presumably natural DRiPs
as well, can be attributed to the rapid degradation of most pro-
teasomal products, which simply do not achieve the steady-
state quantities needed for crosspriming. On the other hand,
our finding that a subset of peptides is resistant to rapid proteol-
ysis would favor the possible contribution of CD8+ T cell priming
via oligopeptide transfer to pAPCs through gap junctions, which
has been elegantly shown to function cultured cells by Neefjes
and colleagues (Neijssen et al., 2005, 2007).
EXPERIMENTAL PROCEDURES
Mice
All experiments used 6- to 10-week-old female C57BL/6J mice purchased
from Taconic Farms. Mice were housed in the animal care facility at National
Institute of Allergy and Infectious Diseases (NIAID) under specific pathogen-
free conditions and maintained on standard mouse chow and water provided
ad libitum. The NIAID Animal Care and Use Committee approved all animal
procedures and studies.Immunity 28, 787–798, June 2008 ª2008 Elsevier Inc. 795
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Peptides were procured and characterized by the Biologic Resource Branch,
NIAID (Rockville, MD). In each case, substances with the predicted mass con-
stituted >95% of the material analyzed. Peptides were dissolved in DMSO at
10 mM and stored at 20C. FITC-labeled peptides (LSLRNPILV[K-3-fluores-
cein]-OH, PA224-233, or SSLENFRAYV[K-3-fluorescein]-OH, PB1-F262-70) were
dissolved in DMSO at a concentration of 10 mg/ml and kept in 20C until use.
Immediately before microinjection, stock peptide solution was diluted to
100 ng/ml in Dulbecco’s P with calcium and magnesium (DPBS). Biotinylated
MHC monomers were provided by the NIAID tetramer facility (Emory Univer-
sity, Atlanta, GA). Cbz-Leu-Leu-Leucinal (zLLL), lactacystin were from Sigma
(St. Louis, MO). Abs to hsp90 (rat IgM Ab 1R2D12p90) and grp94 (rat IgG2a
Ab 9G10) were from StressGen (Victoria, British Columbia, Canada).
Cell Culture and siRNA Transfections
L929 and L-Db (L929 stably transfected with Db molecule) cells were cultured
in DMEM containing 10% FBS; EL-4 thymoma cells (H-2b), TAP-deficient T2,
and T2-D
b (T2 cells stably transfected with D
b molecule) were cultured in
RPMI 1640 containing 10% FBS; and DC-like DC2.4 cells (H-2b) were cultured
in IMDM containing 10% FBS. To generate stable GRP94 siRNA-expressing
HEK293 cell lines, the sequence 50-GGCUCAAGGACAGAUGAUGtt-30 was
cloned into the A pSilencer 2.0-U6 vector (Ambion). The pSilencer 2.0-U6-
GRP94 siRNA and a control, nontargeting pSilencer 2.0-U6 siRNA vector
(scrambled, obtained from Ambion) were transfected into HEK293 cells via
Lipofectamine 2000 according to the manufacturer’s protocol. Cells were se-
lected 36 hr after transfection by addition of puromycin (1 mg/ml) to the media.
Puromycin-resistant clones (both GRP94 siRNA and nontargeting siRNA) were
expanded and clones were screened for knockdown efficiency by immuno-
blotting, via GRP94 antibody DU120. Clones displaying greater than 90%
knockdown were selected. Puromycin-resistant clones from the nontargeting
siRNA were obtained in parallel and screened for normal GRP94 expression,
by immunoblotting with DU120. HEK293 cells were cultured in DMEM contain-
ing 10% FBS. Media and FBS were all from Invitrogen Life Technologies. Tran-
sient siRNA transfections were carried out by transfecting 1–23 106 L-Db cells
in V solution with Amaxa nucleofactor via T-24 program. The target sequences
for HSP90 knockdown were 50-UUUCAGAGCUGUUGCGGUAUU-30 and 50-A
GAGGUUGAUAGAGCGUUUUU- 30 for HSP90a and 50-GGACAAGAUUCG
AUAUGAGUU-30 and 50-GGUGUUAUGUAUUGUGGUUUU-30 for HSP90b
(these sequences have been picked from Dharmacon on target sequences)
used in a mixture of 10 nM each. siRNA specific for GRP94 and Neo were
50-pGGCUCAAGGACAGAUGAUGtt and pAAUGAACUGCAGGACGAGGCAtt
used at 10 nM each. All siRNAs were purchased from Dharmacon (Lafayette,
CO). For maximal knockdown, transfection was repeated after 4 days and cells
were harvested for experiments 4 days after the second transfection. Knock-
down effectiveness was determined by immunoblotting with GRP94- and
HSP90-specific antibodies.
rVV Infections
rVVs containing minigenes encoding PA224-233, NP366-374, and PB1-F262-70
peptides in the cytosol or targeted to the ER were generated as described
for other minigene-expressing rVVs (Anton et al., 1997) Cells were infected
at a multiplicity of infection (MOI) of 10 for 20 min at 37C with mixing every
few minutes in balanced salt solution containing 0.1% bovine serum albumin
(BSS/BSA). Cells were then incubated at 37C in growth media for the remain-
der of the assay in the presence of 25 mg/ml cytosine arabinoside (Sigma, St.
Louis, MO). Protein synthesis was inhibited by the addition of cycloheximide
and emetine (Sigma, St. Louis, MO) to a final concentration of 25 mg/ml
each. Brefeldin A (BFA) (Sigma, St. Louis, MO) was added to a final concentra-
tion of 10 mg /ml.
Phage Ab Generation
Selection of phage antibodies on biotinylated MHC complexes was pre-
formed, as described (Lev et al., 2002). In brief, a large human Fab library
containing 4 3 1010 different Fab clones was used for the selection with de-
creasing amounts of biotinylated MHC-peptide complexes (25 mg for the first
round and 5 mg for the following rounds). Streptavidin-coated magnetic beads
(200 ml for the first round of selection and 100 ml for the following rounds) were
incubated with Phage mixture for 15 min at RT. The beads were washed exten-796 Immunity 28, 787–798, June 2008 ª2008 Elsevier Inc.sively 12 times with PBS/0.1% Tween + 2% milk and additional two washes
with PBS. Bound phages were then eluted with triethylamine (100 mM,
5 min at RT) followed by neutralization with Tris-HCl (1 M, pH 7.4) and used
to infect E. coli TG1 cells (at OD600 = 0.5) for 30 min at 37
C. The diversity of
the selected antibodies was determined by DNA fingerprinting with a restriction
endonuclease (BstNI), which is a frequent cutter of antibody V gene se-
quences. The Fab DNA of different clones was PCR amplified with the primers
pUC-reverse (50-AGCGGATAACAATTTCACACAGG-30) and fd-tet-seq (50-TT
TGTCGTCTTTCCAGACGTTAGT-30 ), followed by digestion with BstNI (NEB,
Beverly, MA) (2 hr, 60C) and analysis on agarose gel electrophoresis (data
not shown).
Expression and Purification of Soluble Recombinant Fab Abs
Fab antibodies were expressed and purified as described (Lev et al., 2002).
BL21 cells were grown to OD600 = 1.0 and induced to express the recombinant
Fab antibody by the addition of 1 mM isopropyl b-D-thiogalactoside (IPTG) for
3 hr at 30C. Proteins were extracted with B-PER solution (Pierce, Rockford,
IL) and applied onto a prewashed TALON column (BD, Palo Alto, CA), and
bound Fabs were eluted with 0.5 ml of 100 mM imidazole in PBS. The eluted
Fabs were dialyzed against PBS (overnight, 4C) to remove residual imidazole.
ELISA with Phage Clones and Purified Fab Antibodies
The binding specificities of individual phage clones and soluble Fabs were de-
termined by ELISA with biotinylated MHC-peptide complexes. ELISA plates
(Falcon) were coated 1 hr at 37C with BSA-biotin (1 mg/well). The plates
were washed and incubated (O.N. at 4C) with streptavidin (1 mg/well), washed
extensively, and further incubated (1 hr, RT) with 0.25 mg/well of MHC-peptide
complexes. The plates were blocked for 30 min at RT with PBS/2% skim milk
and subsequently were incubated for 1 hr at RT with phage clones (109
phages/well) or various concentrations of soluble purified Fab. After washing,
the plates were incubated with HRP-conjugated/anti-human Fab antibody (for
soluble Fabs) or HRP-conjugated anti-M13 phage (for phage-displayed Fabs).
Detection was performed with tetramethylbenzidine reagent (Sigma-Aldrich,
St. Louis, MO).
Flow Cytometry
Db-peptide amounts were determined by incubating cells for 30 min on ice with
20 mg/ml purified Fab antibody. Cells were then washed and incubated for
20 min with Cy5-conjugated anti-human antibody. Cellular Cy5 amounts
were determined on a FACScalibur cytofluorograph (Beckton Dickinson, San
Jose, CA) with CellQuest (Beckton Dickinson) software or LSR II (Beckton
Dickinson, San Jose, CA) with FACSDiva (BD) software, and data were
analyzed with FlowJo (Tree Star, San Carlos, CA) software.
Microscopy and FRAP Analysis
Cells were examined and manipulated with a Leica TCS-SP5 DMI6000 with
8000 Hz resonant scanner and 403 1.25 NA oil objective (Leica Microsystems,
Germany). The microscope was equipped with a Cube & the Box environmen-
tal chamber (Life Imaging Services, Switzerland). Cells were maintained at
37C in 95%/5% air/CO2 mixture. Peptides were microinjected into cells
with an Eppendorf FemtoJet microinjector system (Eppendorf, NY). Cells
were also transfected with eGFP or mCherry-HSP90a plasmids as controls
with Amaxa nucleofactor with T-24 program. Prior to FRAP, a rectangular
9 mm 3 35 mm area was positioned on a microinjected cell with a bleaching
area of 6 mm 3 13 mm size placed in the center of the cells. 20 frames in
0.01 s were collected before bleaching was performed for 0.2 s at the maxi-
mum laser power of 458, 476, and 488 nm laser lines. Fluorescence recovery
was monitored at a collection rate of 100 frames per 0.01 s. At least 50 cells for
each condition were measured in more than three independent experiments.
FRAP recovery half-times were calculated with Leica Application Suite
Advanced Fluorescence software.
Extracting Antigenic Peptides from rVV Minigene-Infected Cells,
HPLC Run, and Measure of CTL Responses
5 3 108 L929 and 1.25 3 108 L-Db cells were infected with rVV- NP366-372 or
rVV-PA224-233 at 20 pfu:cell. Cells were harvested 3 hr after infection, snap fro-
zen, and resuspended in 8 ml 0.1% TFA/H2O. After adding 3 ml of 1% TFA/
H2O, cells were disrupted by >20 strokes in a Dounce homogenizer, sonicated,
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Peptide-Based Crossprimingand rotated on wheel for 30 min at 4C. The lysate was pelleted by low-speed
centrifugation, and the supernatant was passed through a 0.45 mM syringe
filter and then a 3K cut-off filter (Macrosep, filtron 3K, Cat OD003C36, Pall
Filtron Corp., Northborough, MA). The filtrate was speed dried with vacuum
to a volume of less then 400 ml. The sample was filtered through a 0.45 mM mi-
crofilter that was previously washed with 0.1% TFA solution before use and
then directly loaded onto a HPLC C-18 column (Deltapack, Waters). Fractions
were collected every tenth of a minute from 10 min after injection until 38.8 min
(3 3 96-well plates) and stored at 4C. ICS was performed as described for
crosspriming experiments with HPLC fractions to stimulate CD8+ T cell lines
propagated in vitro by stimulation with NP366-374 or PA224-233.
Crosspriming Experiments with Intracellular Cytokine Staining
L929 or HEK293 cells were infected at 10 MOI with rVVs expressing the IAV-
derived peptides as minigenes for 6 hr before UV irradiation. After washing,
10 million cells were injected i.p. into each B6 mouse. Six days later, splenic
and peritoneal L929 cells from primed animals were suspended in RPMI
1640 medium plus 10% FBS and 10 mM HEPES buffer and seeded at 2 3
106 cells/well in U-bottom, 96-well plates. Peptides were added to wells to a fi-
nal concentration of 0.5 mM. Cells were incubated initially for 1–2 hr at 37C
and then for 3 hr with brefeldin A (BFA; Sigma-Aldrich, St. Louis, MO) at
10 mg/ml. Cells were then stained with CyChrome anti-CD8a mAb on ice for
30 min, washed, and fixed with 1% paraformaldehyde in PBS at room temper-
ature for 20 min, then further stained with FITC-conjugated anti-IFN-g in PBS
containing 0.1% saponin (Sigma-Aldrich). Stained cells were analyzed on
a FACSCalibur (BD Biosciences, Sunnyvale, CA) with live-gate on the CD8+
cells. A total of 150,000 cells were normally acquired and analyzed with FlowJo
software (TreeStar, Ashland, OR).
SUPPLEMENTAL DATA
Two figures are available at http://www.immunity.com/cgi/content/full/28/6/
787/DC1/.
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